PENYULUHAN VAKSINASI COVID-19: PERSIAPAN PREVAKSIN DAN TINDAKAN PASCA VAKSIN

Authors

  • (*) Wiwiek Probowati,  Fakultas Kedokteran Universitas Duta Kristen Wacana, Yogyakarta
  • Tejo Jayadi,  Fakultas Kedokteran Universitas Duta Kristen Wacana, Yogyakarta
  • Brenda Miriane Rustam,  Fakultas Kedokteran Universitas Duta Kristen Wacana, Yogyakarta
  • Agatha Maheswari Adita Putri,  Fakultas Kedokteran Universitas Duta Kristen Wacana, Yogyakarta

(*) Corresponding Author

DOI:

https://doi.org/10.21460/servirisma.2022.22.19

Keywords:

Counseling, COVID-19, Vaccine

Abstract

There were 1.69 million COVID-19 cases in Indonesia as of April 2020, of which 1.35 million recovered and 40,858 cases died. This result cannot be regarded as being low because Indonesia is the top-ranked nation in Southeast Asia and the country with the 18th-highest number of COVID-19 cases. Indonesia officially began giving out vaccines to the populace on January 13, 2021, yet some are still hesitant to take advantage of the government's free vaccine program. This effort aims to raise public awareness of the value of the COVID-19 vaccine, identify some circumstances that preclude the administration of the vaccine, and provide management in the event of adverse reactions to immunization (AEFI).The approach taken entails counseling, group discussions, and evaluation of the community's comprehension through pre- and post-tests administered by residents of Miliran village. The anticipated outcome is that the community's paradigm regarding COVID-19 immunization in Miliran village was able to shift, allowing for proper COVID-19 vaccination. The community in Miliran village responded favorably to the counseling, increasing the value of the posttest and their motivation to raise knowledge of the COVID-19 vaccine.

References

Ahn, D.-G. Et al. (2020). ‘Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Corona virus Disease 2019 (COVID-19).’, Journal of microbiology and biotechnology, 30(3), pp.313–324. doi:10.4014/jmb.2003.03011.

Bhattacharya, M. et al. (2020). ‘Development of epitope-based peptide vaccine against novel corona virus 2019 (SARS-COV-2): Immuno informatics approach’, Journal of Medical Virology, 2019, pp.0–2. doi:10.1002/jmv.25736

Chen, W. H. et al. (2020). ‘The SARS-CoV-2 Vaccine Pipeline: an Overview’, Current Tropical Medicine Reports. Current Tropical Medicine Reports, pp.1-4. doi:10.1007/s40475-020-00201-6

Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A comprehensive status report. Virus research, 288, 198114. https://doi.org/10.1016/j.virusres.2020.198114

Nicole Lurie, M.D, et al. (2020). ‘New england journal’, Developing Covid-19 Vaccines at Pandemic Speed,1,pp.1–5

Park, T. et al. (2020). ‘Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2’, bioRxiv, p.2020.02.22.951178. doi:10.1101/2020.02.22.951178

Peeri, N.C. et.al. (2020). ‘The SARS, MERS and novel corona virus (COVID-19) epidemics, the newest and biggest global health threats: what lesson shave we learned?’, International Journal of Epidemiology, pp.1–10. doi:10.1093/ije/dyaa033.

Prompetchara, E., Ketloy, C.and Palaga, T.(2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic’, Asian Pacific journal of allergy and immunology, 38(1), pp. 1–9. doi: 10.12932/AP-200220-0772

Raveendran, A. V., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: An overview. Diabetes & metabolic syndrome, 15(3), 869–875. https://doi.org/10.1016/j.dsx.2021.04.007

Robson, B. (2020). ‘Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus’, Computers in Biology and Medicine. Elsevier Ltd,119,p.103670. doi:10.1016/j.compbiomed.2020.103670.

Shang, W. et al. (2020). ‘The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines’, npj Vaccines. Springer US, 5(1), pp.2–4.doi:10.1038/s41541-020-0170

Sohrabi, C. et al. (2020). ‘World Health Organization declares global emergency: A review of the 2019 novel corona virus (COVID-19)’, International Journal of Surgery. Elsevier,76 (February), pp.71–76.doi:10.1016/j.ijsu.2020.02.034

Sun, P. et al. (2020). ‘Understanding of COVID-19 based on current evidence’, Journal of Medical Virology, pp.0–1. doi:10.1002/jmv.25722.

Zhang, J. Et al. (2020). ‘Progress and Prospects on Vaccine Development against SARS-CoV-2’, Vaccines 2020, 8(2), p.153. doi:10.3390/VACCINES8020153

Zhang, L. And Liu,Y. (2020). ‘Potential interventions for novel corona virus in China: A systematic review’, Journal of Medical Virology, 92(5),pp.479-490. doi:10.1002/jmv.25707

Downloads

Published

2022-11-30

How to Cite

Probowati, W. ., Jayadi, T. ., Rustam, B. M. ., & Putri, A. M. A. . (2022). PENYULUHAN VAKSINASI COVID-19: PERSIAPAN PREVAKSIN DAN TINDAKAN PASCA VAKSIN. Servirisma, 2(2), 77–84. https://doi.org/10.21460/servirisma.2022.22.19

Issue

Vol. 2 No. 2 (2022): Servirisma : Jurnal Pengabdian kepada Masyarakat

Section

Articles

License

Copyright (c) 2022 Wiwiek Probowati

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish articles in SERVIRISMA agree on the following rules:
1. The author grants non exclusive royalty free rights, and is willing to publish articles online and complete (full access). With such rights SERVIRISMA reserves the right to save, transfers, manages in various forms, maintains and publishes articles while keeping the author's name as the copyright owner.
2. Each author contained in the article has contributed fully to the substance and intellectual, and is accountable to the public. If in the future there is a copyright infringement notification then this will be responsibility of the author, not SERVIRISMA .